The Purolite AP+50 affinity chromatography resin has a 50-micron bead size that offers dynamic binding capacity of the AP resin platform while providing durability for monoclonal antibody capture.
Communication between the manufacturing plant and retail stores. | Image Credit: © Cagkan - © Cagkan - stock.adobe.com
Ecolab Life Sciences is launching its new Purolite AP+50 affinity chromatography resin at the Biotechnology Innovation Organization (BIO) International Convention, which is being held in Boston from June 16–19, 2025. The new resin, according to a June 16, 2025 press release (1), can optimize operations during the antibody manufacturing process.
The affinity chromatography resin has a 50-micron bead size that provides dynamic binding capacity of the AP resin platform and durability for monoclonal antibodies. It uses Ecolab’s patented Jetted resin bead manufacturing technology, which enables consistent and shorter lot-to-lot lead times.
“The ability to effectively improve process economics while maintaining purity is the gold standard of resin purification. As pharmaceutical and biotech companies seek to increase savings and improve business continuity, they are requiring innovative solutions to accelerate and de-risk manufacturing,” Meeta Gulyani, senior vice president and general manager, Ecolab Bioprocessing, said in the press release. “Our resins are designed to help customers improve their product development platforms and implement next-generation manufacturing processes as well as enhance dual sourcing strategies that can reduce costs and bolster supply chains.”
The new resin joins the company’s Purolite Resin toolbox for dealing with complex purification challenges. Purolite DurA Cycle A50, a protein A chromatography resin for large-scale purification processes, was launched at the 2024 BIO event.
“The launch of DurA Cycle chromatography resin underscores Ecolab’s 100-year heritage of innovation and ongoing investment in Purolite, reaffirming our commitment to the bioprocessing industry. This new resin enables biologic developers to increase manufacturing efficiencies, reduce their cost of goods, and accelerate the delivery of innovation to the clinic,” said Srini Paluri, senior vice-president and general manager at Purolite, in a June 3, 2024, company press release (2).
Ecolab also announced its new bioprocessing applications laboratory in King of Prussia, Pa., on May 14, 2025 (3). The facility supports the company’s customers with process development for purification of biotherapeutic molecules, including technical support from small-scale to full commercial production, and provides manufacturing-scale chromatography columns.
“Our new Bioprocessing Applications Lab marks a significant milestone in our ability to be a global technical partner to our customers around the world,” Jennifer Sorrells, PhD, vice president of research and development, Ecolab Life Sciences, said in the press release (3). “This facility demonstrates our commitment to delivering best-in-class bioprocessing solutions by pairing Ecolab’s innovative resin toolbox with deep domain expertise to optimize the purification process. We are dedicated to empowering our customers to accelerate the delivery of life-saving therapies to market."
Stacey Treichler, senior director of global marketing and strategy, Purolite, an Ecolab company, spoke with BioPharm International® at the 2024 CPHI Milan event about current trends in the biopharma industry and innovations in purification resins and some of Ecolab’s approaches to complex modalities (4).
In the interview, Treichler said that complex modalities, binding sites, and improving cost of goods were some factors to consider in resin technology. “The manufacturing process can be harsh on [complex modalities]. When you treat those drugs with low pH, harsh chemicals, harsh conditions, they may aggregate, they may lose their folding, and they might not display the critical quality attributes that drug developers are looking for coming out of the manufacturing process,” she explained. The full interview can be found on BioPharmInternational.com.
Ecolab will be giving a technical presentation during the BIO event at the BPI Theatre on Tuesday, June 17 at 2:40 p.m. EST. Ecolab can also be found at booth #1971.
Personalized CRISPR Therapy Successfully Treats Infant With Rare, Incurable CPS1 Deficiency
May 16th 2025A pediatric patient with a rare genetic disorder safely received a personalized CRISPR therapy, marking the first known case of a personalized CRISPR-based medicine administered to a single patient.
